5291-26-9 Usage
Description
1-Azabicyclo[2.2.2]octan-3-one, 2-methyleneis a bicyclic chemical compound with the molecular formula C8H13NO. It features a nitrogen heteroatom and a carbonyl functional group, making it a versatile intermediate for various applications.
Uses
Used in Pharmaceutical and Agrochemical Industries:
1-Azabicyclo[2.2.2]octan-3-one, 2-methyleneis used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure allows for the development of new compounds with potential therapeutic and pesticidal properties.
Used in Flavor and Fragrance Industry:
1-Azabicyclo[2.2.2]octan-3-one, 2-methyleneis also utilized in the production of flavor and fragrance compounds, where its specific chemical properties contribute to the creation of unique scents and tastes.
Used in Neurological Disorder Research:
1-Azabicyclo[2.2.2]octan-3-one, 2-methylenehas been studied for its potential use in the treatment of neurological disorders. Its interaction with biological systems is of interest to researchers seeking new therapeutic approaches for such conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 5291-26-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,2,9 and 1 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 5291-26:
(6*5)+(5*2)+(4*9)+(3*1)+(2*2)+(1*6)=89
89 % 10 = 9
So 5291-26-9 is a valid CAS Registry Number.
5291-26-9Relevant articles and documents
Substituted azabicyclic moieties for the treatment of disease
-
, (2008/06/13)
The invention provides compounds of Formula I: 1wherein m1 is 0 or 1; m2 is 1 or 2; R1 is —H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or phenyl; R2 is —H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or phenyl, provided that when m1 is 1 at least one of R1 and R2 is —H; or a pharmaceutically acceptable salt, pharmaceutical composition, a pure enantiomer or racemic mixture thereof. The invention also provides a method for treating a disease or condition in a mammal, wherein the α7 nicotinic acetylcholine receptor is implicated and for treating diseases where there is a sensory-gating deficit in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of Formula I. These compounds may be in the form of pharmaceutical salts or compositions, and may be in pure enantiomeric form or may be racemic mixtures.
